RYR1 and ovarian carcinoma: Furthermore, RyR have also been theorized to influence cells’ sensitivity to paclitaxel and doxorubicin and to control the activation of the unfolded protein response (UPR) in OVCAR-3 ovarian carcinoma cells [115].